TNFRSF10D and prostate cancer: Interestingly, another study [42] reported that the combined treatment of prostate cancer cells (LNCaP and PC3) with TRAIL and chemotherapeutic agents overcame their resistance by triggering caspase activation; in the same way Sanlioglu et al. [43] indicated that DcR2 siRNA and adenovirus delivery of TRAIL dramatically affected the tumorigenic potential of prostate cancer LNCaP and DU 145 cells.